Protein C Deficiency and Acute Myocardial Infarction in the Third Decade

Steven M. Hacker, MD, Brian D. Williamson, MD, Steven Lisco, MD, James Kure, MD, Michael Shea, MD, and Bertram Pitt, MD

Protein C deficiency has been associated with a predisposition to venous thrombosis and thromboembolism. Arterial thrombosis has been seen much less frequently and may require other vascular risk factors. Here we describe a young patient with protein C deficiency presenting with an acute myocardial infarction (AMI).

A 28-year-old white man, with a history of cardiac contusion, was transferred on June 22, 1990 for further management after an AMI. On March 24, 1989, 15 months before his AMI, the patient sustained a myocardial contusion from a motor vehicle accident. This was manifested by a transient right bundle branch block, which appeared to have resolved on subsequent electrocardiograms. After this episode he was asymptomatic until June 19, 1990, when he developed substernal chest pressure radiating to the left shoulder, with diaphoresis, nausea and vomiting. Electrocardiogram revealed Q waves in leads I and aVL, and 2 mm ST elevation in leads I, aVL, and V1 to V6. Eight hours after the onset of pain he received recombinant tissue-type plasminogen activator and systemic streptokinase were given. Creatine phosphokinase peaked at 4,200 IU. He was administered nitroglycerin, full-dose heparin and lidocaine, and was transferred to our hospital.

As a child he had asthma. He was receiving no medications at the time of presentation. There was a 15 pack-year history of cigarette use but he had not smoked in the preceding 2 years. He worked as a machine operator and denied alcohol or drug abuse. His family history was remarkable for a father with protein C deficiency based on a history of recurrent thrombembolism and a protein C activity of 47%. His paternal uncle died from AMI at age 35 years. Two follow-up cardiac catheterizations revealed a marked decrease in the size of the left main thoracic, with apical akinesia and otherwise normal myocardial wall motion. He was discharged while receiving warfarin, atenolol and aspirin. His first protein C antigen level obtained while he was in the hospital was 54% (normal 70 to 140%). His total cholesterol was 167 mg/dl, triglyceride level 129 mg/dl, high-density lipoprotein 44 mg/dl and low-density lipoprotein 102 mg/dl. During the hospitalization his hemoglobin was 13.9 g/dl, hematocrit was 40%, and platelet count varied from 200,000 to 494,000 per µl (normal 200,000 to 400,000/µl). There was no evidence of liver disease or vitamin K deficiency, as the transaminases were normal, albumin was 4.5 g/dl, and coagulation studies revealed a prothrombin time of 12.4 seconds and a partial thromboplastin time of 27.4 seconds. His fibrinogen was 311 mg/dl and fibrin split products were <8 µg/ml. The Westergren sedimentation rate was normal at 12 mm/hour.

Protein C deficiency is a hereditary disorder transmitted in a codominant fashion. Heterozygous persons have <60% of normal plasma levels of protein C, whereas homozygous persons have no detectable levels of protein C. The homozygous state usually presents in the neonatal period as a devastating disease called purpura fulminans neonatalis. The heterozygous state generally comes to clinical attention in the late teens or early twenties, manifested as superficial thrombotic episodes, deep venous thrombosis, pulmonary embolus or, less frequently, arterial thrombosis.

The anticoagulant protein C and its cofactor, protein S, require vitamin K for the post-translational step that adds a γ-carboxyl group to glutamic acid residues. This step occurs in the liver and is inhibited by warfarin. Procoagulant factors such as II, VII, IX and X also must undergo this carboxylation to function as procoagulants. Except for protein S, all of the vitamin K-dependent proteins circulate as zymogens that must be cleaved to form active serum proteases. Protein C is activated by an interaction between thrombin and thrombomodulin at the surface of the endothelial cell. Thrombomodulin is an intrinsic membrane protein...
of the endothelial cell. When thrombin binds to thrombomodulin, protein C is cleaved and activated much more readily than in the circulation. The majority of activation occurs in the capillary beds, where the proportion of endothelial cell surface (and therefore thrombomodulin) to circulating blood volume is high. Activated protein C acts as an anticoagulant by cleaving and inactivating factors V and VIII, which normally serve to promote the activity of factors Xa and IXa, respectively. Activated protein C has also been shown to increase the activity of the fibrinolytic system. Protein C therefore represents a mechanism for the endothelial cell surface to maintain a hemostatic balance, and deficiency of the factor would create an increased tendency for thrombosis.

Protein C deficiency is well known to be associated with thromboembolic disease. Although most reported cases of thromboses have occurred in the venous system, arterial thrombosis has occurred on occasion. Coller et al described a 28-year-old man with protein C deficiency and a smoking history who had recurrent deep venous thromboses, pulmonary embolism and AMI. Cardiac catheterization at the time of AMI revealed a thrombus occluding the left anterior descending coronary artery, without coronary atherosclerosis. This patient had coronary artery bypass surgery and was discharged while receiving warfarin. The patient later discontinued warfarin on his own and developed left radial and ulnar artery occlusions.

A report in 1987 estimated that 1 in 300 adults are heterozygous for protein C deficiency, although low protein C levels did not, by themselves, appear to explain an increased risk of thrombosis. It is likely that other factors in addition to protein C deficiency contribute to the development of thrombosis, such as damaged endothelium, vascular stasis, or other imbalances between procoagulants and anticoagulants. Therefore, any injury to the endothelial cells that affects proper expression of thrombomodulin, synthesis of protein S, or Va inactivation could potentially lead to a hypercoagulable state and thrombotic complications in the presence of a low protein C level.

The preceding cardiac contusion may have predisposed our patient to his AMI. Although the contusion occurred 15 months before the infarction, blunt chest trauma has been associated with late coronary artery stricture presenting 10 months later. Cardiac contusion with delayed AMI in a protein C-deficient patient has never been reported.

It appears that this patient's protein C deficiency in the presence of other vascular risk factors (i.e., contusion, remote history of cigarette smoking and a family history of premature AMI) may predispose to early AMI. Furthermore, young patients with AMI and a family history suggestive of hypercoagulability should undergo hematologic evaluation, including a check of protein C levels. In patients diagnosed with protein C deficiency and a history of recurrent thromboembolism, warfarin would be the therapy of choice to prevent subsequent episodes of thrombosis.

Upright Retrograde P Waves During Ventricular Tachycardia

Ray Parkin, MB, BS, George Nikolic, MB, BS, and David H. Spodick, MD, DSc

The morphology and axis of retrograde atrial activation have been well defined: a negative deflection in leads II, III and aVF, reflecting a frontal plane axis of −31 to −100 degrees. Retrograde P waves upright in the same leads are well documented but exceedingly rare in clinical electrocardiography. When observed in association with broad ventricular complexes, they can be mistaken for upright P waves of sinoatrial initiation and can be responsible for resulting misdiagnoses. An example of ventricular tachycardia with positive yet undoubtedly retrograde P waves is described below.

The patient, a 63-year-old man, had prolonged weakness and lightheadedness at rest with diaphoresis, dizziness and blurred vision, but no chest pain. These symptoms recurred in a milder form 9 years after a myocardial infarction. Electrocardiography revealed ventricular bigeminy with occasional runs of ventricular tachycardia. He was given lido-